Posters

A novel approach to chronic severe hypotonia

Poster Details

First Author: O.Abd AlRahman SPAIN

Co Author(s):    A. Rodriguez   J. Alió                 

Abstract Details

Purpose:

To date the evidence for the efficacy and clinical improvement of single intra- ocular autologous platelet-rich plasma (PRP) injection in patients with chronic ocular hypotony.

Setting:

This new surgical technique was carried at Vissum Alicante.

Methods:

Platelet rich plasma (E-PRP) is used to enhance and stimulate wound healing; this enhancing effect is attributed to essential growth factor and cell adhesion molecules. Five cases were presented to our clinic with different causes of progressive complicated chronic hypotony. First: 49 years old Axenfield Rieger’s man following express micro-valve implantation with mitomycin C. Second: 75 years old female with traumatic corneal micro-perforation. Third: 7 years old girl with chronic juvenile uveitis. Fourth and fifth: Two ladies aging 50&88 years old following Cy-pass valve implantation. All were injected with 0.3 ml of E-PRP once in the anterior chamber.

Results:

Intraocular pressure (IOP) was measured by Goldman’s applanation tonometry after intracameral E-PRP injection. 1st hour it was +/- 25 mmHg then 6 hours later it became +/- 15mm Hg. During the follow-up periods of at least 1 year, mean IOP was controlled and remained stable with no filtration or hypotony were observed. YAG laser was done 2 weeks after injection to dissolve the remnants of clotted E-PRP in the anterior chamber. The distant unaided visual acuity was improved from counting fingers before surgery to reach +/- 0.6. Complications of chronic hypotony as corneal and macular edema were totally resolved.

Conclusions:

Intra cameral injection of platelet-enriched plasma in the form obtained in ophthalmology, E-PRP, is a reliable and effective surgical coadjuvant to treat many causes leading to severe progressive ocular hypotony and return intraocular pressure to its normal and stable state with no intra or postoperative complications.

Financial Disclosure:

None